| Name | Title | Contact Details |
|---|---|---|
Sherry Kan |
Vice President, Marketing and Product Management | Profile |
Richard Chen |
Chief Medical Officer and Senior Vice President of R&D | Profile |
John Lyle |
VP Assay Development R&D | Profile |
Susan Moriconi |
Vice President of People and Chief Human Resources Officer | Profile |
Arsanis is a leader in the discovery and development of monoclonal antibodies (mAbs) for the targeted immunotherapy of serious infections. Monoclonal antibodies have transformed the treatment of a wide range of diseases from cancer to immune system disorders. In infectious diseases, mAbs can target directly specific pathogens or their virulence mechanisms to avoid pathogenic processes in the infected individual, including resistant strains that give rise to serious infections. Unlike traditional antimicrobials that often target both pathogenic and non-pathogenic organisms in a non-specific way (e.g., broadly killing all Gram-positive bacteria), Arsanis` monoclonal antibodies selectively focus on specific pathogens and pathogenic processes. These targeted immunotherapies address critical infections while minimizing the collateral damage from antimicrobial overuse, resistance, and microbiome disruption. We believe that the ability to selectively and safely target causative pathogens provides a new way of preventing and treating infections in high-risk patients, and can generate both clinical and health economic benefits to patients and providers, ushering in a new era in infection prevention and management.
Woodside Senior Communities is a Green Bay, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cellular Technology is a Beachwood, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We are harnessing the #gut brain axis & the #CNS to develop a new class of therapeutics for people with neurological diseases & disorders
Advance Nanotech Inc is a New York, NY-based company in the Healthcare, Pharmaceuticals, & Biotech sector.